Pharma Innocation Programme Singapore (PIPS) – Automated evaluation of environmental impacts of pharma manufacturing processes

The Pharma Innovation Programme Singapore (PIPS) is an industry-led platform designed to strategically and synergistically combine public sector research capabilities with the domain expertise of the pharmaceutical industry. The project’s goal is to enhance productivity and operational efficiency within Singapore’s pharmaceutical sector by leveraging novel manufacturing technologies and data analytics. The automated evaluation of environmental impacts of pharmaceutical manufacturing processes is spearheaded by Prof. Alexei Lapkin. The project aims to develop best-in-class solutions for the rapid assessment of environmental impacts within the complex framework of medicine production.

CARES has sub-contracted the research and development work to its spin-off company, Chemical Data Intelligence (CDI) Pte Ltd. With proprietary data and expertise in productizing software for the chemical industry, CDI is well-positioned to deliver this project. The approach involves combining data-driven modeling, first principles models, and hybrid models to create a predictive tool for assessing life cycle impacts. This tool will enhance the ability to evaluate and mitigate the environmental footprint of pharmaceutical manufacturing processes.